Duloxetine Plus Piracetam and Cognition
at dose range of 10~30 mg/kg in rodents [13] . In forced swim test, the immobility period was significantly reduced at 10 mg/ kg dose [14, 15] . In addition to 5-HT and NE reuptake inhibitors, nootropic agents like piracetam [16] also play an important role in cognition. The dose range of piracetam described in package inserts of Nootrpil ® is 2.4~12 gm per day [17] . The resulting dose range would be 34 to 171 mg/kg for an adult of 70 kg. Navarro et al. [17] showed therapeutic activity of piracetam at 100 mg/kg dose. Therefore, piracetam monotherapy was considered at 100 mg/kg dose in present study. The precise mechanism of action of piracetam is not clear [18] . Reports suggest better mitochondrial functioning and metabolism of glucose with piracetam treatment [19] . It also has ability to restore the cell membrane alteration in the aging brain [20, 21] . The combination of piracetam and duloxetine may result in augmentation of nootropic activity due to their different mechanism of action. Therefore, the present study was planned to investigate the nootropic effect of piracetam combination with duloxetine in mice.
MATERIALS AND METHODS

Animals
Male Swiss Albino mice weighing 25~30 gm (3 months old) were procured from Bharat Serum Ltd, Thane. They were stored kept in a temperature (22~24 o C) and humidity (50~60%) controlled central animal house facility under light (12 h) and dark (12 h) illumination cycle. Animals were given free access to standard food and water. Experiments were performed between 12.00~16.00 h. Each animal model i.e. Elevated plus maze (EPM),
Morris water maze (MWM) and brain monoamine estimation was conducted on separate set of animals. In each set, animals were randomly distributed into 4 groups (n=6/group; 1 set=24 animals; 3 experiments=72 animals). The arena of EPM was cleaned using 70% ethyl alcohol solution before placing each mouse. Experimental protocols used in present were approved by the Institutional Animal Ethics Committee (Project approval number CPCSEA/IAEC/SPTM/P-08-2013), Government of India, New Delhi.
Drug solutions and treatment
Drugs were administered through intra-peritoneal route. Normal saline (0.9% w/v NaCl) was used to prepare drug solutions. Each animal received treatment 1 h before test session in EPM (on 2 nd day) and Morris water maze (MWM-on 6 th day).
Euthanasia was performed 1 h before treatment in the estimation of brain monoamine. Each animal model had 4 groups. Control group (Group I) received normal saline (10 ml/kg). Treatment of duloxetine (10 mg/kg; Dr. Reddy' s Laboratories Ltd.), piracetam (100 mg/kg; UCB India Pvt. Ltd.), and combination of duloxetine (5 mg/kg)+piracetam (50 mg/kg) were given to Group II, III, and IV, respectively.
Spatial memory tests
EPM
The protocol used to evaluate transfer latency (TL) in EPM was described by Dhingra et al. [22] . Time taken by each animal to reach the closed arm is recorded as the TL. In brief, 2 open arms On the first day (the acquisition session), each animal was exposed to EPM for 90 seconds. Time taken by animal to reach the closed arm was recorded as the transfer latency (TL). Animals failed to enter in closed arm in 90 seconds were excluded from study. On second day (the retention session), each animal was put into the open arm and the TL was recorded for maximum 90 seconds. The SMART v2.5.21 videotracking system (Panlab Harvard Apparatus, spain) was used to evaluate TL.
Morris water maze (MWM)
MWM test is used to evaluate the hippocampal-dependent learning, including acquisition of spatial memory and long-term spatial memory. The protocol of MWM described by BromleyBrits et al. [23] was used to determine the percent time spent in target quadrant. Drug treatments were given to mice 60 min before test on 6 th trial day. In brief, the pool having 150 cm diameter and, 
Brain monoamine estimation by HPLC with fluorescence detector (HPLC-FD) method
Heads were dropped in ice cold perchloric acid (0.1 M) immediately after euthanasia. After weighing brain, separation of cerebral cortex, hippocampus, and remaining brain parts were separated, weighed, and homogenized in 2 ml of ice cold 0.1 M perchloric acid. Analysis of monoamine levels in cerebral cortex, hippocampus, and whole brain (whole brain=cerebral cortex+hippocampus+remaining brain tissue) was performed using method described by Choudhary et al. [24] and Madepalli et al. [25] (HPLC-Shimadzu, LC-2010C HT, autosampler with FD-RF-20A-prominence, Shimadzu). The method was optimized inhouse [26] . 
Statistical analysis
The Graphpad InStat for 32 bit Windows version 3.06 was used to perform statistical analysis. Comparison between different groups was performed using ANOVA followed by Tukey' s honest significant difference (HSD) post-hoc test. Data was represented as mean±SEM values (per group n=6/group). 
RESULTS AND DISCUSSION
In EPM, duloxetine treatment showed no significant change in TL ( Fig. 1) than control group. The escape latency on 1 st day with visible platform was similar in all animals in MWM ( Fig. 2A) . In the training and acquisition with invisible platform (2~5 days), (Fig. 2B) . Duloxetine treatment showed no significant change in time spent in target quadrant (Fig. 2C ) than control group. The results of duloxetine treated group in EPM ( Fig. 1) and MWM ( Fig. 2C ) are in-line with the published reports [27] . Published report suggest no benefits with acute or sub-acute treatment duloxetine in cognition treatment [27] , however clinical studies have reported cognition related benefits with 8 weeks [8] and 12 weeks [28] of duloxetine treatment in depressed patients. The significant increase in brain monoamine profile of duloxetine is in line with the published reports [29, 30] . These reports suggest that duloxetine increases DA levels not only in cerebral cortex [29, 30] , but also in hippocampus [26] and nucleus accumbens region [30] . In present study, piracetam treated group showed significant decrease in TL (Fig. 1) , as compared to control group. Patil et al. [31] have reported similar decrease in TL after piracetam treatment in EPM. The decrease in TL was not significant in remaining groups (Fig. 1) . In MWM, the time spent in target quadrant was significantly increased in piracetam treated group, as compared to control group (Fig. 2C) . One way ANOVA F values of EPM, MWM, and brain monoamine are given in Table 1 . The significant increase in brain monoamine profile of lower dose of piracetam treatment in present study is in line with the published reports [32, 33] . The decrease in TL observed in EPM and the increase in time spent in target quadrant observed in MWM were not statistically significant in combination treated group, as compared to control, duloxetine, and piracetam treated groups, separately. Cortex and hippocampus regions play important role in cognition and emotions [1] . Combination treated group showed significant increase in brain monoamine levels in hippocampus, cerebral cortex, and whole brain when compared against respective control groups (Fig. 3) . However, same treatment failed to increase in monoamine profile in hippocampus, cerebral cortex, and whole brain when compared against duloxetine and piracetam treated groups (Fig. 3) . There was exception of NE levels in cerebral cortex when compared against duloxetine treated group (Fig. 3A) . The possible reason behind failure to produce augmentation of nootropic activity may be the interactions between piracetam and duloxetine. Everss et al. [34] reported decrease in memory and learning tasks due to interaction between piracetam and amitriptyline. However, the report hasn't described the reason [34] . Therefore, the study focusing on the effect of acute and chronic dosing of duloxetine and piracetam combination on electrophysiological analysis, neurogenesis, biogenic amine pathway activation/deactivation, drug metabolism, and related drug interaction studies may help in understanding the present study outcomes.
